Magnetic Fields / Dose Cancer Research Results

MF, Magnetic Fields: Click to Expand ⟱
Features: Therapy
Magnetic Fields can be Static, or pulsed. The most common therapy is a pulsed magnetic field in the uT or mT range.
The main pathways affected are:
Calcium Signaling: -influence the activity of voltage-gated calcium channels.
Oxidative Stress and Reactive Oxygen Species (ROS) Pathways
Heat Shock Proteins (HSPs) and Cellular Stress Responses
Cell Proliferation and Growth Signaling: MAPK/ERK pathway.
Gene Expression and Epigenetic Modifications: NF-κB
Angiogenesis Pathways: VEGF (improving VEGF for normal cells)
PEMF was found to have a 2-fold increase in drug uptake compared to traditional electrochemotherapy in rat melanoma models

Pathways:
- most reports have ROS production increasing in cancer cells , while decreasing in normal cells.
- ROS↑ related: MMP↓(ΔΨm), ER Stress↑, UPR↑, GRP78↑, Ca+2↑, Cyt‑c↑, Caspases↑, DNA damage↑, cl-PARP↑, HSP↓, Prx,
- Raises AntiOxidant defense in Normal Cells: ROS↓, NRF2↑, SOD↑, GSH↑, Catalase↑,
- lowers Inflammation : NF-kB↓, COX2↓, Pro-Inflammatory Cytokines : NLRP3↓, IL-1β↓, TNF-α↓, IL-6↓, IL-8↓
- inhibit Growth/Metastases : TumMeta↓, TumCG↓, VEGF↓(mostly regulated up in normal cells),
- cause Cell cycle arrest : TumCCA↑,
- inhibits Migration/Invasion : TumCMig↓, TumCI↓, TNF-α↓,
- inhibits glycolysis /Warburg Effect and ATP depletion : HIF-1α↓, PKM2↓, GLUT1↓, LDH↓, HK2↓, PFKs↓, PDKs↓, ECAR↓, OXPHOS↓, GRP78↑, Glucose↓, GlucoseCon↓
- inhibits angiogenesis↓ : VEGF↓, HIF-1α↓, Notch↓, FGF↓, PDGF↓, EGFR↓, Integrins↓,
- Others: PI3K↓, AKT↓, STAT↓, Wnt↓, β-catenin↓, ERK↓, JNK, - SREBP (related to cholesterol).
- Synergies: chemo-sensitization, chemoProtective, cytoProtective, RadioSensitizer, RadioProtective, Others(review target notes), Neuroprotective, Hepatoprotective, CardioProtective,

- Selectivity: Cancer Cells vs Normal Cells

Non-Static Magnetic Fields (AC / Pulsed / Oscillating MF)
Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Reactive oxygen species (ROS) ↑ ROS (P→R); often sustained (G) ↑ ROS (P); ↔/↓ net ROS (R→G) P, R, G Upstream redox perturbation MF perturbs electron/radical dynamics: normal cells often adapt (ROS setpoint ↓), cancer cells less so
2 NRF2 antioxidant response ↔ / insufficient NRF2 induction (R→G) ↑ NRF2 activation (R→G) R, G Adaptive redox defense Explains mixed ROS direction in normal cells (initial ↑ then adaptive ↓)
3 Glutathione (GSH) homeostasis ↓ GSH (R→G) ↔ or transient ↓ (R) with recovery (G) R, G Redox buffering capacity GSH depletion reflects sustained oxidative load; recovery indicates successful adaptation
4 Superoxide dismutase (SOD) / antioxidant enzymes ↔ or inadequate enzyme upshift (G) ↑ SOD/GPx/CAT capacity (G) G Longer-term antioxidant remodeling Often the “endpoint” readout that correlates with ROS-normalization in normal tissue
5 Mitochondrial ETC / respiration ↓ ETC efficiency; ↑ electron leak (P→R) ↔ mild, reversible ETC perturbation (P→R) P, R Bioenergetic destabilization ETC perturbation is a mechanistic bridge between MF exposure and ROS/ΔΨm changes
6 Mitochondrial membrane potential (ΔΨm / MMP) ↓ ΔΨm (R); may progress (G) ↔ preserved or reversible dip (R) R, G Mitochondrial dysfunction thresholding ΔΨm loss typically follows ROS/ETC disruption rather than preceding it
7 Ca²⁺ signaling (VGCC / ER–mitochondria Ca²⁺ flux) ↑ dysregulated Ca²⁺ influx/transfer (P→R); overload may persist (G) ↑ transient Ca²⁺ signaling (P); homeostasis restored (R→G) P, R, G Stress signal amplification Ca²⁺ dysregulation links ROS/ETC perturbation to ER stress and mitochondrial dysfunction (amplifies ΔΨm loss and UPR commitment)
8 Mitochondrial permeability transition pore (MPTP) ↑ MPTP opening propensity (R); sustained opening possible (G) ↔ transient or closed (R→G) P, R, G Commitment point for mitochondrial failure MPTP opening integrates ROS, Ca²⁺ overload, and ΔΨm loss; acts as a threshold event converting reversible stress into irreversible mitochondrial dysfunction
9 ER stress / UPR ↑ ER stress (R); CHOP-commitment possible (G) ↑ adaptive UPR (R); resolves (G) R, G Proteostasis stress Often downstream of ROS + Ca²⁺ handling perturbations
10 DNA damage (oxidative) ↑ damage markers (R→G) ↔ or repaired (G) R, G Checkpoint pressure Generally secondary to ROS; interpret as stress consequence not “direct genotoxicity”
11 LDH / glycolytic flux ↓ glycolytic performance (R→G) ↔ flexible substrate switching (R→G) R, G Metabolic vulnerability Redox imbalance can destabilize high-rate glycolysis in cancer-biased contexts
12 Thioredoxin system (Trx / TrxR) ↓ functional reserve / overload (R→G) ↔ preserved capacity (G) R, G Parallel antioxidant system stress Useful when GSH-only does not explain redox phenotype
Time-Scale Flag: TSF = P / R / G
  P: 0–30 min (physical / electron / radical effects)
  R: 30 min–3 hr (redox signaling & stress response)
  G: >3 hr (gene-regulatory adaptation)
MPTP: opening represents a mitochondrial commitment event integrating ROS and Ca²⁺ stress; sustained opening indicates irreversible bioenergetic failure.


Dose, Dosage: Click to Expand ⟱
Source:
Type:
Drug dosage vs efficacy, and actual dosage number of research papers.


Scientific Papers found: Click to Expand⟱
3473- MF,    Therapeutic use of pulsed electromagnetic field therapy reduces prostate volume and lower urinary tract symptoms in benign prostatic hyperplasia
- Human, BPH, NA
*Inflam↓, *Dose↝, *other?,
2250- MF,  MNPs,    Confronting stem cells with surface-modified magnetic nanoparticles and low-frequency pulsed electromagnetic field
- Review, NA, NA
*Ca+2↑, *Dose↝, *BioAv↓,
192- MF,    The use of magnetic fields in treatment of patients with rheumatoid arthritis. Review of the literature
- Review, Arthritis, NA
*Dose↝, Pain↓, Inflam↓, Sleep↑,
4103- MF,    Comparing the Effects of Long-term Exposure to Extremely Low-frequency Electromagnetic Fields With Different Values on Learning, Memory, Anxiety, and β-amyloid Deposition in Adult Rats
- in-vivo, NA, NA
*Dose↝, *memory↑, *ROS↑, *MDA↑,
4119- MF,    Therapeutic potential and mechanisms of repetitive transcranial magnetic stimulation in Alzheimer’s disease: a literature review
- Review, AD, NA
*cognitive↑, *memory↑, *motorD↑, *eff↑, *eff↑, *Dose↝, *Dose↝, *Dose↝, *BDNF↑, *Aβ↓, *eff↑,
4111- MF,    Coupling of pulsed electromagnetic fields (PEMF) therapy to molecular grounds of the cell
- Review, Arthritis, NA
*Inflam↓, *Cartilage↑, *Pain↓, *QoL↑, *Dose↝, *VEGF↑, *NO↑, *TGF-β↑, *MMP9↓, *PGE2↑, *GPx3↑, *SOD2↑, *Catalase↑, *GSR↑, *Ca+2↑,
4102- MF,    Modulation of antioxidant enzyme gene expression by extremely low frequency electromagnetic field in post-stroke patients
- Human, Stroke, NA
*Catalase↑, *SOD1↑, *SOD2↑, *GPx1↑, *GPx4↑, *Dose↝,
4098- MF,    Extremely low frequency electromagnetic field (ELF-EMF) reduces oxidative stress and improves functional and psychological status in ischemic stroke patients
- Trial, Stroke, NA
*antiOx↑, *cognitive↑, *Dose↝,
4097- MF,    Theta Frequency Electromagnetic Stimulation Enhances Functional Recovery After Stroke
- Trial, Stroke, NA
*motorD↑, *eff↑, *Dose↝,
4096- MF,    Extremely Low‐Frequency and Low‐Intensity Electromagnetic Field Technology (ELF‐EMF) Sculpts Microtubules
- in-vitro, AD, NA
*p‑tau↓, *neuroP↑, *Dose↝,
4095- MF,    Frequency-tuned electromagnetic field therapy improves post-stroke motor function: A pilot randomized controlled trial
- Trial, Stroke, NA
*Dose↝, *motorD↑,
4094- MF,    EMAGINE-Study protocol of a randomized controlled trial for determining the efficacy of a frequency tuned electromagnetic field treatment in facilitating recovery within the subacute phase following ischemic stroke
- Study, Stroke, NA
*neuroP↑, *Dose↝,
5533- MF,    Magnetic field-induced drug permeability in liposome vesicles
- in-vitro, Nor, NA
*Dose↝, *CellMemb↑, *other↝,
5531- MF,    Effect of low frequency, low amplitude magnetic fields on the permeability of cationic liposomes entrapping carbonic anhydrase: I. Evidence for charged lipid involvement
- in-vitro, NA, NA
Dose↝, CellMemb↑,
4571- MF,    Magnetic Fields and Reactive Oxygen Species
- Review, NA, NA
*ROS⇅, *ETC↓, Dose↝, Dose↝,
4015- MF,    Evaluation of the PTEN and circRNA-CDR1as Gene Expression Changes in Gastric Cancer and Normal Cell Lines Following the Exposure to Weak and Moderate 50 Hz Electromagnetic Fields
- in-vitro, GC, AGS - in-vitro, Nor, HU02
*PTEN↑, PTEN↓, Dose↝,
4355- MF,    Ambient and supplemental magnetic fields promote myogenesis via a TRPC1-mitochondrial axis: evidence of a magnetic mitohormetic mechanism
- in-vitro, Nor, C2C12
*mt-OCR↑, *mt-ROS↑, *ECAR↑, *Dose↝, *Ca+2↑, *ATP↑, *other↑, *eff↓, *eff↝,
4349- MF,    Long-term effect of full-body pulsed electromagnetic field and exercise protocol in the treatment of men with osteopenia or osteoporosis: A randomized placebo-controlled trial
- Trial, ostP, NA
*BMD↑, *Pain↓, *QoL↑, *toxicity↓, *Dose↝, *Inflam↓,
4148- MF,    Increase in Blood Levels of Growth Factors Involved in the Neuroplasticity Process by Using an Extremely Low Frequency Electromagnetic Field in Post-stroke Patients
- Human, Stroke, NA
*neuroP↑, *BDNF↑, *Dose↝,
3740- MF,    Gamma rhythm low field magnetic stimulation alleviates neuropathologic changes and rescues memory and cognitive impairments in a mouse model of Alzheimer's disease
- in-vivo, AD, NA
*cognitive↑, *Dose↝, *Aβ↓, *PSD95↑,
185- MFrot,  MF,    Case Report: End-Stage Recurrent Glioblastoma Treated With a New Noninvasive Non-Contact Oncomagnetic Device
- Human, GBM, NA
TumVol↓, Dose↝, cognitive↑,
187- MFrot,  MF,    Method for noninvasive whole-body stimulation with spinning oscillating magnetic fields and its safety in mice
- in-vivo, GBM, NA
selectivity↑, ROS↑, *ROS∅, *toxicity∅, ETC↓, TumVol↓, Dose↝,
516- MFrot,  immuno,  MF,    Anti-tumor effect of innovative tumor treatment device OM-100 through enhancing anti-PD-1 immunotherapy in glioblastoma growth
- vitro+vivo, GBM, U87MG
TumCP↓, Apoptosis↑, TumCMig↓, ROS↑, PD-L1↑, TumVol↓, eff↑, *toxicity∅, eff↑, *toxicity∅, Dose↝, tumCV↓, TumCI↓,
184- MFrot,  MF,    Rotating Magnetic Fields Inhibit Mitochondrial Respiration, Promote Oxidative Stress and Produce Loss of Mitochondrial Integrity in Cancer Cells
- in-vitro, GBM, GBM
ROS↑, mitResp↓, mtDam↑, Dose↝, MMP?, OCR↓, mt-H2O2↑, eff↓, SDH↓, Thiols↓, GSH↓, TumCD↑, Casp3↑, Casp7↑, MPT↑, Cyt‑c↑, selectivity↑, GSH/GSSG↓, ETC↓,

Showing Research Papers: 1 to 24 of 24

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 24

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress

GSH↓, 1,   GSH/GSSG↓, 1,   mt-H2O2↑, 1,   ROS↑, 3,   Thiols↓, 1,  

Mitochondria & Bioenergetics

ETC↓, 2,   mitResp↓, 1,   MMP?, 1,   MPT↑, 1,   mtDam↑, 1,   OCR↓, 1,   SDH↓, 1,  

Cell Death

Apoptosis↑, 1,   Casp3↑, 1,   Casp7↑, 1,   Cyt‑c↑, 1,   TumCD↑, 1,  

Transcription & Epigenetics

tumCV↓, 1,  

Proliferation, Differentiation & Cell State

PTEN↓, 1,  

Migration

TumCI↓, 1,   TumCMig↓, 1,   TumCP↓, 1,  

Barriers & Transport

CellMemb↑, 1,  

Immune & Inflammatory Signaling

Inflam↓, 1,   PD-L1↑, 1,  

Drug Metabolism & Resistance

Dose↝, 8,   eff↓, 1,   eff↑, 2,   selectivity↑, 2,  

Clinical Biomarkers

PD-L1↑, 1,  

Functional Outcomes

cognitive↑, 1,   Pain↓, 1,   Sleep↑, 1,   TumVol↓, 3,  
Total Targets: 34

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress

antiOx↑, 1,   Catalase↑, 2,   GPx1↑, 1,   GPx3↑, 1,   GPx4↑, 1,   GSR↑, 1,   MDA↑, 1,   ROS↑, 1,   ROS⇅, 1,   ROS∅, 1,   mt-ROS↑, 1,   SOD1↑, 1,   SOD2↑, 2,  

Mitochondria & Bioenergetics

ATP↑, 1,   ETC↓, 1,   mt-OCR↑, 1,  

Core Metabolism/Glycolysis

ECAR↑, 1,  

Transcription & Epigenetics

other?, 1,   other↑, 1,   other↝, 1,  

Proliferation, Differentiation & Cell State

PTEN↑, 1,  

Migration

Ca+2↑, 3,   Cartilage↑, 1,   MMP9↓, 1,   TGF-β↑, 1,  

Angiogenesis & Vasculature

NO↑, 1,   VEGF↑, 1,  

Barriers & Transport

CellMemb↑, 1,  

Immune & Inflammatory Signaling

Inflam↓, 3,   PGE2↑, 1,  

Synaptic & Neurotransmission

BDNF↑, 2,   PSD95↑, 1,   p‑tau↓, 1,  

Protein Aggregation

Aβ↓, 2,  

Drug Metabolism & Resistance

BioAv↓, 1,   Dose↝, 19,   eff↓, 1,   eff↑, 4,   eff↝, 1,  

Clinical Biomarkers

BMD↑, 1,  

Functional Outcomes

cognitive↑, 3,   memory↑, 2,   motorD↑, 3,   neuroP↑, 3,   Pain↓, 2,   QoL↑, 2,   toxicity↓, 1,   toxicity∅, 3,  
Total Targets: 48

Scientific Paper Hit Count for: Dose, Dosage
24 Magnetic Fields
4 Magnetic Field Rotating
1 magnetic nanoparticles
1 immunotherapy
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:172  Target#:1114  State#:%  Dir#:4
wNotes=0 sortOrder:rid,rpid

 

Home Page